Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus OXILAN 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus OXILAN 300.
HYPAQUE SODIUM 20% vs OXILAN-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent